Studies highlight reduced hypoglycemia risk for people with type 2 diabetes who switch to “next-gen” basal insulins Toujeo or Tresiba
Research
The latest research in type 1 diabetes, type 2 diabetes, prediabetes, and beyond. Here you’ll find information on experimental therapies, new data and results, and scientific findings.
35 readers recommended
CANVAS study presented at ADA 2017 highlights heart and kidney protection for type 2 diabetes drug Invokana, and questions persist over an increased risk of amputations
45 readers recommended
Research reveals improved A1c and weight loss benefits for people with type 1 diabetes on sotagliflozin, but a slightly increased risk of DKA
38 readers recommended
FDA Approves New GLP-1 Label on Victoza to show that the medicine makes hearts healthier!
37 readers recommended
New CONCEPTT trial results show improved newborn health and more time-in-range in women with type 1 diabetes using CGM during pregnancy
48 readers recommended
The latest evidence on Saxenda shows that three years of treatment with the drug lowers risk for type 2 diabetes by an impressive 79%
31 readers recommended
Trial shows that a pill version of Ozempic (semaglutide) can lower A1c by as much as 1.5% and also support weight loss
33 readers recommended
Read about combo drug Xultophy, Toujeo vs. Tresiba, diabetes apps, the do-it-yourself community, FreeStyle Libre real-world data, and more!
41 readers recommended
The results were so positive it was deemed unethical to keep giving people placebo instead of Invokana, an SGLT-2 inhibitor approved for type 2 diabetes
23 readers recommended
Physicians, diabetes educators, and research scientists share their own health bright spots in food and exercise, technology, and more
30 readers recommended
An app uses blood sugar readings and other diabetes information to provide personalized guidance to workouts, along with exercise videos specifically for people with...
31 readers recommended
Ketogenic (low-carb + high-fat) diet and remote coaching to “reverse” type 2 diabetes shows 60% of participants had type 2 “reversed," 94% of insulin users reduced or...
35 readers recommended
Farxiga and Zynquista are recommended for approval for people with type 1 diabetes in Europe with emphasis on DKA safety; EMA approval likely in coming months and hope...
37 readers recommended
From clinical expertise and personal experience as a type 1, Dr. Sherr shares valuable (and exciting) perspectives on diabetes treatments.
45 readers recommended
Xeris’ Glucagon Rescue Pen, designed as an auto-injector, features a ready-to-use liquid glucagon – a safer and more convenient treatment option for severe hypoglycemia
38 readers recommended
Learn more about JDRF’s efforts in finding a cure for type 1 diabetes and read highlights from experts’ discussions on SGLT inhibitors in type 1 and Beyond A1C
51 readers recommended
Heart benefits of the SGLT-2 inhibitor pill beyond blood sugars and weight loss for people with type 2 diabetes
25 readers recommended
Zynquista was not approved by the FDA; Complete Response Letter suggests the FDA is weighing safety concerns of the SGLT-1/2 dual inhibitor for type 1 diabetes
34 readers recommended
A huge milestone that makes Forxiga the first pill for people with type 1 diabetes in Europe
37 readers recommended
Zealand Pharma shared positive trial results for its dasiglucagon – 99% of participants recovered from hypo within 15 minutes of treatment